Trials / Unknown
UnknownNCT06094530
18F-FAPI-RGD PET/CT in Various Tumor Types
Clinical Evaluation of 18F-FAPI-RGD PET/CT for Imaging of Fibroblast Activation Protein and Integrin avb3 in Various Tumor Types
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (estimated)
- Sponsor
- Sichuan Provincial People's Hospital · Academic / Other
- Sex
- All
- Age
- 10 Years – 80 Years
- Healthy volunteers
- Accepted
Summary
The clinical feasibility of 18F-FAPI-RGD PET/CT will be evaluated in 100 patients with various types of tumor, and the results will be compared with those of 18F-FDG.
Detailed description
The aim of this study is to evaluate, in patients with various types of tumor, the radiotracer uptake and clinical feasibility of 18F-FAPI-RGD PET/CT compared with those of 18F-FDG PET/CT. To evaluate the diagnostic performance of 18F-FAPI-RGD and 18F-FDG PET imaging, the results of the visually interpreted PET images will be compared with the histopathologic results (via surgery or biopsy), which are used as the gold standard for the final diagnosis. For patients for whom tissue diagnosis is not applicable, clinical and radiographic follow-up data will be used as the reference standard to validate the PET/CT findings.
Conditions
Timeline
- Start date
- 2023-04-10
- Primary completion
- 2024-09-01
- Completion
- 2024-10-01
- First posted
- 2023-10-23
- Last updated
- 2023-10-23
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06094530. Inclusion in this directory is not an endorsement.